Search Result

Results for "

osteoporosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Acetyl-CoA Carboxylase (1) Acyltransferase (1) Adrenergic Receptor (2) Akt (17) AMPK (6) Amyloid-β (1) Androgen Receptor (8) AP-1 (1) Apoptosis (75) Arrestin (2) Aryl Hydrocarbon Receptor (3) Autophagy (29) Bacterial (16) Bcl-2 Family (9) Biochemical Assay Reagents (4) Calcineurin (1) Calcium Channel (4) CaMK (4) Cannabinoid Receptor (1) Carnitine Palmitoyltransferase (CPT) (1) Casein Kinase (2) Caspase (11) CaSR (10) Cathepsin (18) CDK (2) CGRP Receptor (5) Chloride Channel (4) Cholinesterase (ChE) (5) Collagen (1) COX (4) Cytochrome P450 (1) Dengue Virus (1) Dipeptidyl Peptidase (4) DNA/RNA Synthesis (5) Drug Derivative (6) Drug Intermediate (1) Drug Metabolite (3) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (28) Environmental Pollutants (17) Epoxide Hydrolase (2) ERK (20) Estrogen Receptor/ERR (42) FABP (1) FAK (1) Farnesyl Transferase (3) Fatty Acid Synthase (FASN) (1) Fc Receptor (FcR) (1) Ferroptosis (11) FGFR (1) Fluorescent Dye (1) FOXO (1) Fungal (2) GHSR (2) Glycosidase (1) GSK-3 (2) Heme Oxygenase (HO) (4) HIF/HIF Prolyl-Hydroxylase (15) Histone Demethylase (1) Histone Methyltransferase (1) HIV (2) HIV Protease (1) HSP (1) HSV (2) IFNAR (2) IKK (2) Influenza Virus (3) Insulin Receptor (1) Integrin (3) Interleukin Related (17) Isotope-Labeled Compounds (36) JAK (6) JNK (13) Keap1-Nrf2 (14) LPL Receptor (1) LRRK2 (1) MAP3K (5) MAPKAPK2 (MK2) (2) MARK (1) MDM-2/p53 (5) Melanocortin Receptor (2) Methionine Adenosyltransferase (MAT) (1) mGluR (11) Mitochondrial Metabolism (2) Mixed Lineage Kinase (2) MMP (11) Monoamine Oxidase (3) mTOR (16) MyD88 (1) Neprilysin (1) NF-κB (61) NO Synthase (12) NOD-like Receptor (NLR) (8) Nuclear Factor of activated T Cells (NFAT) (9) Osteopontin (1) P-glycoprotein (1) P2X Receptor (3) p38 MAPK (32) PARP (2) PD-1/PD-L1 (2) PDGFR (2) PGE synthase (2) Phosphatase (8) Phosphodiesterase (PDE) (8) PI3K (16) Piezo Channel (3) PIN1 (1) PINK1/Parkin (2) PKA (5) PKC (1) PKG (1) PPAR (7) Progesterone Receptor (4) Prostaglandin Receptor (1) Proton Pump (4) PTHR (11) Pyk2 (1) Pyroptosis (1) RANKL/RANK (20) RAR/RXR (3) Ras (1) Reactive Oxygen Species (ROS) (16) Reference Standards (51) RIP kinase (2) ROS Kinase (7) RUNX (2) RXFP Receptor (2) SARS-CoV (2) Ser/Thr Protease (1) sFRP-1 (1) Sirtuin (1) SOD (4) Src (4) STAT (19) Survivin (2) TGF-beta/Smad (10) TGF-β Receptor (2) Thyroid Hormone Receptor (14) TNF Receptor (11) Toll-like Receptor (TLR) (8) Transmembrane Glycoprotein (1) Tyrosinase (4) UGT (1) VD/VDR (9) Wnt (24) Zinc Finger Protein (1) β-catenin (18)
By Research Areas:	Cancer (140) Cardiovascular Disease (52) Endocrinology (59) Infection (29) Inflammation/Immunology (125) Metabolic Disease (209) Neurological Disease (57)
Click Chemistry:	Azide (1) Alkynes (2)

378

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

116

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0059

Teriparatide Maximum Cited Publications 11 Publications Verification Human parathyroid hormone-(1-34); hPTH (1-34)	PTHR Thyroid Hormone Receptor	Others Cancer
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research .

HY-P2273

Calcitonin (human)	CGRP Receptor	Metabolic Disease
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .

HY-10003

Alfacalcidol 5 Publications Verification 1-hydroxycholecalciferol; 1.alpha.-Hydroxyvitamin D3	Environmental Pollutants VD/VDR	Metabolic Disease
Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis .

HY-N0681

D-Pantothenic acid hemicalcium salt 5+ Cited Publications Calcium pantothenate; Calcium D-pantothenate; Vitamin B5 calcium salt	Environmental Pollutants Apoptosis Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
D-Pantothenic acid hemicalcium salt is an orally active vitamin that reduces patulin in apple juice. D-Pantothenic acid hemicalcium salt removes ROS. D-Pantothenic acid hemicalcium salt has antibacterial and immunomodulatory activities. D-Pantothenic acid hemicalcium salt also has the effect of improving osteoporosis and obesity .

HY-B0257

Levonorgestrel 2 Publications Verification D-Norgestrel	Apoptosis Caspase Bcl-2 Family Survivin	Endocrinology Cancer
Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma .

HY-13738

Raloxifene 15+ Cited Publications Keoxifene; LY156758 free base; LY139481	Estrogen Receptor/ERR	Cancer
Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-B0631

Alendronic acid 5+ Cited Publications	NF-κB Interleukin Related	Metabolic Disease
Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research .

HY-108685

Alendronate sodium 5+ Cited Publications Alendronic acid monosodium salt	NF-κB Interleukin Related	Metabolic Disease
Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research .

HY-B0302

Etidronic acid 1 Publications Verification Etidronate; HEDPA; HEDP	Environmental Pollutants Apoptosis	Metabolic Disease Cancer
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .

HY-15927

4-Nitrophenyl β-D-glucopyranoside 1 Publications Verification	Biochemical Assay Reagents	Metabolic Disease
4-Nitrophenyl β-D-glucopyranoside is a chromogenic substrate for β-glucosidase. 4-Nitrophenyl β-D-glucopyranoside is converted to a colored product, p-nitrophenol that is easily detected spectrophotometrically at 405 nm when used in a β-glycosidase assay. 4-Nitrophenyl β-D-glucopyranoside is hydrolysed through intramolecular nucleophilic catalysis by the phosphate group in the 2-position. 4-Nitrophenyl β-D-glucopyranoside is promising for research of postmenopausal osteoporosis .

HY-A0037

Lasofoxifene 5 Publications Verification CP-336156	Estrogen Receptor/ERR	Inflammation/Immunology Cancer
Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .

HY-W012980

Isovaleric acid 1 Publications Verification	Environmental Pollutants Endogenous Metabolite PKA AMPK	Metabolic Disease
Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .

HY-N0433

Astragaloside II 1 Publications Verification Astrasieversianin VIII	Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB	Inflammation/Immunology Endocrinology Cancer
Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .

HY-N0257

Epimedin A 4 Publications Verification	PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related	Metabolic Disease Inflammation/Immunology
Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .

HY-110195

Smurf1-IN-A01 3 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others Cancer
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-18312

PF-4618433 5 Publications Verification	Pyk2	Metabolic Disease
PF-4618433 is a potent and selective PYK2 inhibitor, with an IC₅₀ of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration .

HY-B0012

Pamidronic acid 1 Publications Verification	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-15100

Balicatib 2 Publications Verification AAE581	Cathepsin	Inflammation/Immunology
Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC₅₀ values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis .

HY-112569

MAT2A inhibitor 2	Methionine Adenosyltransferase (MAT) NF-κB p38 MAPK	Cancer
MAT2A inhibitor 2 is an inhibitor of methionine adenosine transferase 2A (MAT2A) with oral activity. MAT2A inhibitor 2 can be used in osteoporosis study

HY-B0012A

Pamidronate disodium 1 Publications Verification CGP 23339A	RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin	Metabolic Disease Inflammation/Immunology Cancer
Pamidronate disodium (CGP 23339A), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .

HY-N1941

Isosinensetin	P-glycoprotein Bacterial HIV Protease Phosphatase Reactive Oxygen Species (ROS) NF-κB p38 MAPK ERK JNK Calcium Channel	Infection Metabolic Disease Inflammation/Immunology Cancer
Isosinensetin is a flavonoid compound and an inhibitor of HIV-1 protease and PTP1B (IC₅₀: 2.61 µM; K_i: 0.92 µM). Isosinensetin inhibits P-glycoprotein (P-gp) in MDR1-MDCKII cells. Isosinensetin has multiple activities such as anti-tumor, anti-viral, anti-inflammatory, and antioxidant effects. Isosinensetin can be used in the research of various diseases including cancer, inflammation, osteoporosis, diabetes, etc .

HY-A0038

Lasofoxifene tartrate 5 Publications Verification CP-336156 tartrate	Estrogen Receptor/ERR	Endocrinology Cancer
Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .

HY-A0020S

Eldecalcitol-d6	VD/VDR	Metabolic Disease
Eldecalcitol-d₆ is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.

HY-123047

Tibolone	Progesterone Receptor Androgen Receptor Estrogen Receptor/ERR	Endocrinology
Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .

HY-148350

DS69910557	PTHR	Cancer
DS69910557 is a potent, selective and orally activehuman parathyroid hormone receptor 1 (hPTHR1) antagonist. DS69910557 has antagonistic activity for PTHR1 with an IC₅₀ value of 0.08 μM. DS69910557 can be used for the research of hyperparathyroidism, hypercalcemia of malignancy and osteoporosis .

HY-126109

(±)-8-Prenylnaringenin	Estrogen Receptor/ERR Apoptosis	Metabolic Disease Endocrinology Cancer
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ERα and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-N1403

Tigogenin	Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Tigogenin is a steroidal sapogenins. Tigogenin can inhibit adipocytic differentiation and induce osteoblastic differentiation in mouse bone marrow stromal cells. Tigogenin can inhibit cells proliferation and induce apoptosis. Tigogenin can be used for the researches of cancer, inflammation, immunology, metabolic and cardiovascular disease, such as mammary gland carcinoma, rheumatoid arthritis, osteoporosis and atherosclerosis .

HY-P1252

Parathyroid Hormone (1-34), bovine 3 Publications Verification	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

HY-165607S

MCB-22-174	Piezo Channel Isotope-Labeled Compounds ERK CaMK	Metabolic Disease
MCB-22-174 is a deuterated Piezo1 agonist, with an EC₅₀ value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca ²⁺ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP) .

HY-P3075

pTH-Related Protein (1-34) (human,mouse,rat) pTHrP (1-34)	Thyroid Hormone Receptor	Inflammation/Immunology
pTH-Related Protein (1-34) (human, mouse, rat), a fragment of parathyroid hormone-related protein, is an anabolic agent. pTH-Related Protein (1-34) (human, mouse, rat) can be used for postmenopausal osteoporosis study .

HY-148694

ISX-3	PPAR	Metabolic Disease
ISX-3 is a potent anti-adipogenic and pro-osteogenic agent. ISX-3 increases the expression of PPARγ. ISX-3 has the potential for the research of osteopenia and osteoporosis .

HY-W012980R

Isovaleric acid (Standard)	Reference Standards Endogenous Metabolite AMPK PKA	Metabolic Disease
Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .

HY-149149

Incadronic acid	Bacterial	Infection Metabolic Disease Cancer
Incadronic acid inhibits growth of Dictyostelium discoideum with an IC₅₀ of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the K_i of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC₅₀ of 48 to 228.6 µM .

HY-100953

CYM-5520 1 Publications Verification	LPL Receptor	Metabolic Disease
CYM-5520 is a selective and allosteric sphingosine 1-phosphate receptor 2 (S1PR2) agonist with an EC₅₀ of 480 nM. CYM-5520 does not activate S1PR1, S1PR3, S1PR4 and S1PR5 receptors. CYM-5520 can co-bind in the S1PR2 receptor with S1P. CYM-5520 can be used for osteoporosis research .

HY-122961

Dehydromiltirone 1,2-Didehydromiltirone	NF-κB p38 MAPK	Inflammation/Immunology
Dehydromiltirone (1,2-Didehydromiltirone) is a diterpenoid quinone with an anti-inflammatory effect. Dehydromiltirone prevents liver injury by modifying the MAPK and NF-κB signaling pathways, reducing neuroinflammatory responses, and inhibiting platelet aggregation. Dehydromiltirone can be used for osteoporosis research .

HY-122732

OADS	Chloride Channel	Cardiovascular Disease Neurological Disease
OADS is a Chloride channel antiporter (ClC-ec1) inhibitor (IC₅₀: 29 μM). OADS specifically inhibits the ClC-ec1 antiporter but not the ClC-1 channel. OADS can be used for research of osteoporosis and neurodegenerative and cardiovascular diseases .

HY-W107722

IN04	LRRK2	Endocrinology
IN04 is a inhibitor of leucine-rich repeat kinase 1 (LRRK1). IN04 can completely block the binding of ATP to the human LRRK1 kinase domain, thereby inhibiting the kinase activity of LRRK1. IN04 can significantly impair the bone resorption ability of osteoclasts, with an IC₅₀ value of 5.72 μM. IN04 can be used for the study of osteoporosis .

HY-135702

UBS109	NF-κB	Others
UBS109, as a curcumin analogue, can promote the differentiation and mineralization of osteoblasts. UBS109 shows to regulate bone cell function by activating Smad and inhibiting NF-kB. UBS109 can be used in bone tissue engineering and osteoporosis research .

HY-P0059A

Teriparatide acetate hydrate Human parathyroid hormone-(1-34) acetate hydrate; hPTH (1-34) acetate hydrate	PTHR Thyroid Hormone Receptor	Others Cancer
Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PTH1 receptor agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research .

HY-175703

RANKL-IN-1	RANKL/RANK Reactive Oxygen Species (ROS) NF-κB p38 MAPK ERK JNK MMP	Metabolic Disease
RANKL-IN-1 is a selective and orally active Receptor Activator of Nuclear Factor-κ B Ligand (RANKL) inhibitor with a K_D value of 7.6 μM. RANKL-IN-1 exhibits inhibitory activity and selectivity against osteoclastogenesis with an IC₅₀ value of 0.07 μM and SI of 82.57. RANKL-IN-1binds directly to RANKL and blocks the RANKL-induced activation of the NF-κB and MAPK pathways. RANKL-IN-1 can be used for the research of metabolic disease, such as osteoporosis .

HY-176944

PTH1R agonist 2	PTHR	Metabolic Disease Endocrinology
PTH1R agonist 2 (example 3) is a parathyroid hormone 1 receptor (PTH1R) agonist. PTH1R agonist 2 can be used for research of hypoparathyroidism and osteoporosis .

HY-135588

Raloxifene 6,4'-Bis-β-D-glucuronide	Drug Metabolite	Metabolic Disease
Raloxifene 6,4'-Bis-β-D-glucuronide (compound IV) is a metabolite of Raloxifene. Raloxifene is a selective estrogen receptor antagonist for the prevention of osteoporosis .

HY-179002

(S)-STO021	Estrogen Receptor/ERR	Inflammation/Immunology
(S)-STO021 is a highly selective, orally effective ERβ agonist. (S)-STO021 has a dual activity of inhibiting osteoclast activity and promoting osteoblast activity. (S)-STO021 can be used for research on osteoporosis .

HY-14752

Ronacaleret SB 751689	CaSR	Metabolic Disease Endocrinology
Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis .

HY-15104

Ronacaleret hydrochloride SB 751689A	CaSR	Metabolic Disease Endocrinology
Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis .

HY-14360

MK 1256	Cathepsin	Metabolic Disease
MK 1256 is a highly selective and orally active inhibitor of tissue protease K (Cat K) with an IC₅₀ of 0.62 nM. MK 1256 shows extremely high selectivity towards other tissue proteases (all > 1100 times), with only a slightly lower selectivity for tissue protease F (Cat F) (110 times). MK 1256 exhibits strong anti-bone resorption activity in the osteoporosis model of rhesus monkeys with ovariectomy. MK 1256 can be used for research on osteoporosis .

HY-175669

ANO1-IN-5	Chloride Channel	Metabolic Disease Endocrinology
ANO1-IN-5 is an orally active ANO1 inhibitor with an IC₅₀ of 4.57 μM. J ANO1-IN-5 demonstrates 118-, 642-, and 10000-fold selectivity over α_1A-,α_1B-, andα_1D-AR, respectively. ANO1-IN-5 exhibits significant inhibitory effects on osteoclast differentiation and function. ANO1-IN-5 can used for the study of osteoporosis .

HY-143714

Cathepsin K inhibitor 2	Cathepsin	Inflammation/Immunology
Cathepsin K inhibitor 2 is a potent inhibitor of cathepsin K. Cathepsin K, Cat K is a cysteine protease expressed under the control of CTSK gene and closely related to osteoporosis, whose main function is to hydrolyze collagen. Cathepsin K inhibitor 2 has the potential for the research of osteoarthfitis (extracted from patent WO2021147882A1, compound 78) .

HY-P991659

SCH708980	Interleukin Related	Infection Inflammation/Immunology
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .

HY-125146

BMD4503-2	Wnt	Others
BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis .

Cat. No.	Product Name

HY-L105

Peptide Library

2,520 compounds

Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.

MedChemExpress (MCE) offers a comprehensive collection of 2,520 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Cat. No.	Product Name	Type

HY-D0939

Direct Blue 1 2 Publications Verification Chicago Sky Blue 6B	Fluorescent Dyes
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity .

HY-15001G

Stemregenin 1

SR1

Fluorescent Dyes

Stemregenin 1 (SR1) (GMP) is a GMP-grade Stemregenin 1 (HY-15001). GMP-grade small molecules can be used as adjuvants in cell therapy. Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with an IC₅₀ of 127 nM. Stemregenin 1 (GMP) can competitively bind to AhR and inhibit its nuclear translocation, inhibiting osteoclastogenesis and promoting hematopoietic progenitor cell expansion by blocking the AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. Stemregenin 1 (GMP) can be used for the study of osteoporosis, in vitro expansion of hematopoietic stem cells, and the study of the mechanism of bone metabolic diseases .

HY-15893G

DMOG

Dimethyloxallyl Glycine

Fluorescent Dyes

DMOG (GMP) is the GMP level of DMOG (HY-15893). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

HY-N0390G

L-Glutamine

Fluorescent Dyes

L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

Cat. No.	Product Name	Type

HY-15927

4-Nitrophenyl β-D-glucopyranoside

1 Publications Verification

Biochemical Assay Reagents

4-Nitrophenyl β-D-glucopyranoside is a chromogenic substrate for β-glucosidase. 4-Nitrophenyl β-D-glucopyranoside is converted to a colored product, p-nitrophenol that is easily detected spectrophotometrically at 405 nm when used in a β-glycosidase assay. 4-Nitrophenyl β-D-glucopyranoside is hydrolysed through intramolecular nucleophilic catalysis by the phosphate group in the 2-position. 4-Nitrophenyl β-D-glucopyranoside is promising for research of postmenopausal osteoporosis .

HY-W110927

Alizarin Red S Indicator (4.3-6.3), IND

Biochemical Assay Reagents

Alizarin red S indicator (C.I. 58005) is a reductively active (quinone-based) anthraquinone dye that forms complexes with metal ions (such as zirconium, calcium) or boric acid to label calcium deposition and perform electrochemical sensing functions. Alizarin Red S undergoes reversible redox reactions (for electrochemical detection) and irreversible chelation (for bone staining). Alizarin Red S is mainly used in bone metabolism research (labeling mineralized tissue), sugar detection (boric acid-sugar competition system) and metal ion sensing (such as zirconium ion detection)， and can be used in osteoporosis and metabolic disease research .

HY-15001G

Stemregenin 1

SR1

Biochemical Assay Reagents

HY-W423191

Maltobionic acid

4-O-α-D-Glucopyranosyl-D-gluconic acid

Biochemical Assay Reagents

Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H₂O₂)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .

HY-W145486

Calcium gluconate

Biochemical Assay Reagents

Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .

HY-15893G

DMOG

Dimethyloxallyl Glycine

Biochemical Assay Reagents

HY-N0390G

L-Glutamine

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P0059

Teriparatide Maximum Cited Publications 11 Publications Verification Human parathyroid hormone-(1-34); hPTH (1-34)	PTHR Thyroid Hormone Receptor	Others Cancer
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research .

HY-P2273

Calcitonin (human)	CGRP Receptor	Metabolic Disease
Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .

HY-108742

Abaloparatide 3 Publications Verification BA 058; BIM 44058	PTHR Arrestin	Metabolic Disease Cancer
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .

HY-P11070

SDSSD	Peptides	Others
SDSSD is an osteoblast-targeting peptide. SDSSD selectively binds to periostin on osteoblasts and mediates targeted delivery to these cells. SDSSD can endow calcium phosphate nanocomposites with bone-targeting properties, and these materials exhibit osteointegrative capacity in both in vitro and in vivo models. When conjugated with polyurethane nanomicelles, SDSSD enables targeted delivery of siRNA/microRNA to osteoblasts .

HY-P4823

pTH (1-37) (human)	Thyroid Hormone Receptor	Metabolic Disease
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .

HY-107245

Segetalin B 2 Publications Verification	Estrogen Receptor/ERR Sirtuin RUNX	Metabolic Disease
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .

HY-P5581

Alloferon 1	Peptides	Infection Inflammation/Immunology Cancer
Alloferon 1 is an antiviral and antitumoral peptide. Alloferon 1 stimulates natural cytotoxicity of human peripheral blood lymphocytes. Alloferon 1 also induces IFN synthesis, and enhances antiviral and antitumor resistance in mice. Alloferon 1 also shows anti-inflammatory activity in λ-carrageenan-induced paw edema model. Alloferon 1 can be isolated from the blood of the blow fly Calliphora vicina (Diptera) .

HY-P1252

Parathyroid Hormone (1-34), bovine 3 Publications Verification	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

HY-P2279

Parathyroid hormone (1-34) (rat) 2 Publications Verification	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Parathyroid hormone (1-34) (rat) is a parathyroid hormone. Parathyroid hormone (1-34) (rat) improves both cortical and cancellous bone structure. Parathyroid hormone (1-34) (rat) can be used for the research of osteoporosis .

HY-108742A

Abaloparatide TFA 3 Publications Verification BA 058 TFA; BIM 44058 TFA	Arrestin PTHR	Metabolic Disease Endocrinology Cancer
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .

HY-P3075

pTH-Related Protein (1-34) (human,mouse,rat) pTHrP (1-34)	Thyroid Hormone Receptor	Inflammation/Immunology
pTH-Related Protein (1-34) (human, mouse, rat), a fragment of parathyroid hormone-related protein, is an anabolic agent. pTH-Related Protein (1-34) (human, mouse, rat) can be used for postmenopausal osteoporosis study .

HY-P3637

AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG	Peptides	Inflammation/Immunology
AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis .

HY-P2279A

Parathyroid hormone (1-34) (rat) acetate 2 Publications Verification	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Parathyroid hormone (1-34) (rat) (acetate) is a parathyroid hormone. Parathyroid hormone (1-34) (rat) improves both cortical and cancellous bone structure. Parathyroid hormone (1-34) (rat) can be used for the research of osteoporosis .

HY-P11214

Hydrostatin-TL1 H-TL1	TNF Receptor Integrin NF-κB ERK p38 MAPK JNK Interleukin Related	Inflammation/Immunology
Hydrostatin-TL1 (H-TL1), a nine-amino-acid peptide, is a TNF-α antagonist. Hydrostatin-TL1 can be isolated from the venom gland of sea snake Hydrophis cyanocinctus. H-TL1 competitively inhibits the interaction between TNF-α/TNFR1 and attenuates the cytotoxicity and inflammation of TNF-α. Hydrostatin-TL1 can be used for TNF-α-associated inflammatory diseases, such as rheumatoid arthritis, osteoporosis and inflammatory bowel disease (IBD) research .

HY-P0090A

Calcitonin (salmon) acetate Salmon calcitonin acetate	CGRP Receptor	Cancer
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .

HY-P5929

VnP-16	Integrin FAK	Inflammation/Immunology
VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .

HY-P0007

Elcatonin Carbocalcitonin	Drug Intermediate	Metabolic Disease
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .

HY-P5377

Abz-HPGGPQ-EDDnp Cathepsin K substrate	Ser/Thr Protease	Others
Abz-HPGGPQ-EDDnp (Cathepsin K substrate) is a biological active peptide. (Cathepsins are a class of globular lysosomal proteases, playing a vital role in mammalian cellular turnover. They degrade polypeptides and are distinguished by their substrate specificities. Cathepsin K is the lysosomal cysteine protease involved in bone remodeling and resorption. It has potential as a drug target in autoimmune diseases and osteoporosis.This FRET peptide can be used to monitor selectively cathepsin K activity in physiological fluids and cell lysates. Abz-HPGGPQ-EDDnp [where Abz represents o-aminobenzoic acid and EDDnp represents N -(2, 4-dinitrophenyl)-ethylenediamine], a substrate initially developed for trypanosomal enzymes, is efficiently cleaved at the Gly-Gly bond by cathepsin K. This peptide is resistant to hydrolysis by cathepsins B, F, H, L, S and V, Ex/Em=340 nm/420 nm.)

HY-P1252A

Parathyroid Hormone (1-34), bovine TFA	Thyroid Hormone Receptor	Metabolic Disease
Parathyroid Hormone (1-34), bovine TFA is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .

HY-P1463

Calcitonin, eel Thyrocalcitonin eel	Thyroid Hormone Receptor	Endocrinology
Calcitonin, eel is the thyroid hormone peptide that contributes to the regulation of calcium homeostasis, widely used in the research of postmenopausal osteoporosis.

HY-P1463A

Calcitonin, eel TFA Thyrocalcitonin eel TFA	Thyroid Hormone Receptor	Others
Calcitonin, eel TFA is the thyroid hormone peptide that contributes to the regulation of calcium homeostasis, widely used in the research of postmenopausal osteoporosis .

HY-P10061

Cathepsin K inhibitor 4	Cathepsin	Cancer
Cathepsin K inhibitor 4 is a potent carbohydrazide Cathepsin K inhibitor with IC₅₀s of 13 nM, 269 nM, 296 nM for human, rat, mouse Cathepsin K, respectively .

HY-103303

CRSP-1	CGRP Receptor	Metabolic Disease
CRSP-1 is short for calcitonin receptor-stimulating peptide-1. CRSP-1 inhibits osteoclast formation by inhibiting the formation and activity of multinucleated osteoclast .

HY-P4817

Human PTH-(1-31)	Thyroid Hormone Receptor	Metabolic Disease
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .

HY-P11552

(Asp-Ser-Ser)6 (DSS)6	Peptides	Metabolic Disease
(Asp-Ser-Ser)6 ((DSS)6) is an artificially designed bone-targeting peptide. (Asp-Ser-Ser)6 is used as a ligand to modify apoptotic extracellular vesicles (ApoEVs) in order to enhance the bone targeting and efficacy of ApoEVs in the treatment of osteoporosis. (Asp-Ser-Ser)6 can be used for research on osteoporosis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9958

Denosumab 2 Publications Verification AMG-162	NF-κB Caspase Apoptosis RANKL/RANK	Endocrinology Cancer
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-P9982

Romosozumab 1 Publications Verification AMG-785; CDP-7851	Inhibitory Antibodies	Endocrinology Cancer
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .

HY-P99186

Blosozumab	Inhibitory Antibodies	Others
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .

HY-P990165

Anti-Mouse RANKL/CD254 Antibody (IK22/5)	RANKL/RANK E1/E2/E3 Enzyme NF-κB	Inflammation/Immunology Cancer
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is an anti-mouse RANKL/CD254 IgG2a monoclonal antibody. Anti-Mouse RANKL/CD254 Antibody (IK22/5) inhibits osteoclast formation and activity by specifically blocking the binding of RANKL and RANK. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can inhibit the expression of MuRF1/Trogin-1 and activation of NF-κB. Anti-Mouse RANKL/CD254 Antibody (IK22/5) can be used for research on cancer such as melanoma or colon cancer and osteoporosis .

HY-P991659

SCH708980	Interleukin Related	Infection Inflammation/Immunology
SCH708980 is a humanized monoclonal antibody inhibitor targeting IL-10. SCH708980 has anti-immunosuppressive activity. SCH708980 can be used for visceral leishmaniasis, sepsis-associated kidney injury (SAKI) and osteoporosis research .

HY-P991569

PF-04840082	Wnt	Metabolic Disease Endocrinology
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .

HY-P991365

DS-1501	Transmembrane Glycoprotein	Endocrinology
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991617

AMG-167	Wnt	Cancer
AMG-167 is an anti-cancer monoclonal antibody targeting sclerostin. AMG-167 can be studied in research for osteoporosis .

HY-P991362

GB-223	TNF Receptor	Cancer
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .

HY-P992113

Evabosmig	β-catenin Wnt	Metabolic Disease
Evabosmig is a multispecific antibody targeting SOST, DKK-1 and ALB. Evabosmig can be used for the study of osteoporosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B2156

Menaquinone-4 5+ Cited Publications Vitamin K2(MK-4); Menaquinone K4	Quinones Microorganisms other families Classification of Application Fields Plants Endogenous metabolite Naphthalene Quinones Disease Research Fields Source Classification Cancer	Endogenous Metabolite
Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.

HY-N0528

Linarin 4 Publications Verification Buddleoside; Linarine	Flavonoids Flavones Labiatae Erythrina poeppigiana Plants Source Classification	TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus
Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer .

HY-N0681

D-Pantothenic acid hemicalcium salt 5+ Cited Publications Calcium pantothenate; Calcium D-pantothenate; Vitamin B5 calcium salt	Structural Classification Natural Products other families Classification of Application Fields Other Diseases Plants Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Apoptosis Endogenous Metabolite
D-Pantothenic acid hemicalcium salt is an orally active vitamin that reduces patulin in apple juice. D-Pantothenic acid hemicalcium salt removes ROS. D-Pantothenic acid hemicalcium salt has antibacterial and immunomodulatory activities. D-Pantothenic acid hemicalcium salt also has the effect of improving osteoporosis and obesity .

HY-N0824

Syringin 3 Publications Verification Eleutheroside B	Cardiovascular Disease Structural Classification Classification of Application Fields Simple Phenylpropanols Phenylpropanoids Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Disease Research Fields Araliaceae Source Classification	Environmental Pollutants Autophagy
Syringin (Eleutheroside B) is an active natural phenolic glycoside possessing various pharmacological activities, including anti-inflammatory, anti-irradiation, anti-osteoporosis and anticancer activities. Syringin also can be used to enhance memory, relieve fatigue, improve human cognition and protect ischemia heart against cerebrovascular damage, etc .

HY-N1425

Tiliroside 3 Publications Verification	Flavonols Flavonoids Classification of Application Fields Platanus occidentalis L. Phenols Polyphenols Metabolic Disease Platanaceae Plants Disease Research Fields Source Classification	Others
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a K_i value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .

HY-N1499

Nystose	Structural Classification Polysaccharides Classification of Application Fields Rubiaceae Metabolic Disease Plants Morinda officinalis How Disease Research Fields Saccharides Source Classification	Wnt β-catenin TGF-beta/Smad Bacterial
Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway .

HY-N2037

Higenamine 5+ Cited Publications Norcoclaurine; Demethyl-Coclaurine	Alkaloids Structural Classification Classification of Application Fields Ranunculaceae Phenols Polyphenols Aconitum carmichaeli Debx. Plants Isoquinoline Alkaloids Disease Research Fields Endocrinology Source Classification	MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis
Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N2515

Ginsenoside Rk1 5+ Cited Publications	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-15449

Kaempferide 5+ Cited Publications Kaempferol 4'-O-methyl ether	Infection Flavonols Flavonoids Classification of Application Fields Phenols Polyphenols Alpinia officinarum Hance Plants Disease Research Fields Source Classification Zingiberaceae	Estrogen Receptor/ERR Autophagy Bacterial Influenza Virus Apoptosis PI3K Akt GSK-3 FOXO β-catenin
Kaempferide is an orally active flavonol isolated from Hippophae rhamnoides L. Kaempferide has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. Kaempferide induces apoptosis. Kaempferide promotes osteogenesis through antioxidants and can be used in osteoporosis research .

HY-N0015

Astragalin 15+ Cited Publications Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside	Flavonols Flavonoids Microorganisms Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Thesium chinense Turcz. Source Classification Santalaceae Cancer	Apoptosis NF-κB
Astragalin (Astragaline) a flavonoid with anti-inflammatory, antioxidant, anticancer, bacteriostatic activity. Astragalin inhibits cancer cells proliferation and migration, induces apoptosis. Astragalin is orally active and provides nerve and heart protection, and resistance against and osteoporosis .

HY-N0721

Neoandrographolide 1 Publications Verification Neoandrographiside	Structural Classification Acanthaceae Classification of Application Fields Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species (ROS) Apoptosis
Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .

HY-W012980

Isovaleric acid 1 Publications Verification	Structural Classification Classification of Application Fields Endocrine diseases Metabolic Disease Endogenous metabolite Biological Pesticide Research Agricultural Research Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite PKA AMPK
Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .

HY-N0433

Astragaloside II 1 Publications Verification Astrasieversianin VIII	Triterpenes Classification of Application Fields Leguminosae Terpenoids Other Diseases Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Disease Research Fields Source Classification	Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB
Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .

HY-N3002

α-Arbutin 4-Hydroxyphenyl α-D-glucopyranoside	Monophenols Classification of Application Fields Phenols Metabolic Disease Cosmetic Research Ericaceae Plants Disease Research Fields Source Classification	Tyrosinase
α-Arbutin (4-Hydroxyphenyl α-D-glucopyranoside) is a tyrosinase inhibitor, which is used as an effective skin whiteners. α-Arbutin is promising for research of various diseases such as hyperpigmentation disorders, types of cancers, central nervous system disorders, osteoporosis, diabetes .

HY-N0657

Pinoresinol Diglucoside 1 Publications Verification	Structural Classification Eucommia ulmoides Oliver Classification of Application Fields Lignans Other Diseases Eucommiaceae Phenylpropanoids Plants Disease Research Fields Source Classification	NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K
Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis .

HY-106950

Fosfructose Diphosphofructose; Esafosfan; FDP	Cardiovascular Disease Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Toll-like Receptor (TLR) COX
Fosfructose is an orally active cyclooxygenase-2 inhibitor and Toll-like receptor 4 modulator. Fosfructose reduces the expression of cyclooxygenase-2, thereby decreasing prostaglandin production. By inhibiting the Toll-like receptor 4 signaling pathway, Fosfructose downregulates LPS-induced adhesion molecule expression. Fosfructose is applicable to research related to ischemic stroke, epilepsy, sepsis, myocardial injury, osteoporosis, and ultraviolet B-induced skin damage .

HY-N2393

Kukoamine B 1 Publications Verification	Alkaloids Classification of Application Fields Other Alkaloids Phenols Polyphenols Solanaceae Plants Lycium chinense Miller Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis MMP MAPKAPK2 (MK2) p38 MAPK PI3K Akt Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis .

HY-N0123

Aloin-A 5+ Cited Publications Barbaloin-A	Quinones Structural Classification Liliaceae Classification of Application Fields Anthraquinones Phenols Polyphenols Aloe vera (L.) Burm. f. Plants Disease Research Fields Source Classification Cancer	Wnt
Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .

HY-N0257

Epimedin A 4 Publications Verification	Flavonols Structural Classification Monophenols Flavonoids Classification of Application Fields Other Diseases Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Disease Research Fields Source Classification	PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related
Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .

HY-N2037A

Higenamine hydrochloride 5+ Cited Publications Norcoclaurine hydrochloride	Structural Classification Classification of Application Fields Plants Lindera aggregata (Sims) Kosterm. Alkaloids Phenols Polyphenols Lauraceae Isoquinoline Alkaloids Disease Research Fields Endocrinology Source Classification Cancer	MAP3K MDM-2/p53 ROS Kinase Apoptosis
Higenamine hydrochloride is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-130237

Cinnamtannin B-1	Anthocyans Flavonoids other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) NF-κB Apoptosis
Cinnamtannin B-1 is a anthocyanidin. Cinnamtannin B-1 inhibits the osteoclast formation by inhibiting NF-kB signaling pathway and ROS generation. Cinnamtannin B-1 exhibits antioxidant, anti-inflammatory, antitumor and anti-platelet aggregation activities. Cinnamtannin B-1 is orally active .

HY-N0026

2'-Acetylacteoside 1 Publications Verification 2'-AA	Structural Classification Classification of Application Fields Simple Phenylpropanols Other Diseases Scrophulariaceae Phenylpropanoids Plants Disease Research Fields Brandisia hancei Hook. f. Source Classification	Monoamine Oxidase RANKL/RANK TNF Receptor NF-κB IKK
2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease .

HY-N0546

Ligustroflavone 2 Publications Verification Nuezhenoside	Flavonoids Oleaceae Classification of Application Fields Flavones Ligustrum lucidum Ait. Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .

HY-N1939

Icariside I 3 Publications Verification Icarisid I	Flavonols Structural Classification Monophenols Flavonoids Classification of Application Fields Other Diseases Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Disease Research Fields Source Classification	Apoptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) STAT CDK Bcl-2 Family Aryl Hydrocarbon Receptor JAK Caspase IFNAR PD-1/PD-L1
Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape .

HY-N0507

Rosavin	Simple Phenylpropanols Rhodiola rosea Linn. Crassulaceae Phenylpropanoids Plants Source Classification	TNF Receptor Interleukin Related
Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis .

HY-N0213

Peiminine 5+ Cited Publications Verticinone; Raddeanine	Alkaloids Piperidine Alkaloids Fritillaria thunbergii Miq. Liliaceae Classification of Application Fields Plants Disease Research Fields Source Classification Cancer	Autophagy Caspase Bcl-2 Family PARP p38 MAPK ERK NF-κB Apoptosis
Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models .

HY-N0444

Rubiadin	Quinones Structural Classification Classification of Application Fields Anthraquinones Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS)
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-N1941

Isosinensetin	Flavonoids other families Classification of Application Fields Flavones Plants Inflammation/Immunology Disease Research Fields Source Classification	P-glycoprotein Bacterial HIV Protease Phosphatase Reactive Oxygen Species (ROS) NF-κB p38 MAPK ERK JNK Calcium Channel
Isosinensetin is a flavonoid compound and an inhibitor of HIV-1 protease and PTP1B (IC₅₀: 2.61 µM; K_i: 0.92 µM). Isosinensetin inhibits P-glycoprotein (P-gp) in MDR1-MDCKII cells. Isosinensetin has multiple activities such as anti-tumor, anti-viral, anti-inflammatory, and antioxidant effects. Isosinensetin can be used in the research of various diseases including cancer, inflammation, osteoporosis, diabetes, etc .

HY-N2484

Methylnissolin 2 Publications Verification Astrapterocarpan	Cardiovascular Disease Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Phenols Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Other Flavonoids Disease Research Fields Source Classification	PDGFR ERK
Methylnissolin (Astrapterocarpan) is an osteoclast inhibitor with anti-inflammatory, neuroprotective and antioxidant activities. Methylnissolin downregulates the activation of the MAPK and PI3K/AKT pathways, inhibits the phosphorylation of MAPK1 and AKT1, and blocks PDGF-BB-induced phosphorylation of ERK1/2. Methylnissolin reduces the expression and secretion of proinflammatory mediators, decreases intracellular ROS levels, upregulates antioxidant enzymes, and downregulates osteoclastogenesis markers. Methylnissolin is applicable to research related to ischemic stroke, osteoporosis, cardiovascular diseases, skin aging, etc.

HY-W009208

Calcium L-Threonate 1 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Calcium L-Threonate, a calcium aldonate, is a calcium supplement. Calcium L-Threonate can be used for the study of osteoporosis .

HY-N0008

Orcinol glucoside	Curculigo orchioides Gaertn. Structural Classification Monophenols Phenols Plants Amaryllidaceae Source Classification	Wnt p38 MAPK mTOR Keap1-Nrf2 TGF-β Receptor
Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .

HY-N0705

Curculigoside 5+ Cited Publications	Curculigo orchioides Gaertn. Monophenols Neurological Disease Classification of Application Fields Phenols Plants Amaryllidaceae Disease Research Fields Source Classification Cancer	JAK STAT NF-κB
Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the JAK/STAT/NF-κB signaling pathway .

HY-108059

β-Cryptoxanthin (3R)-β-Cryptoxanthin	Other Terpenoids Structural Classification Capsicum annuum L. other families Neurological Disease Classification of Application Fields Terpenoids Solanaceae Plants Endogenous metabolite Disease Research Fields Source Classification	Drug Derivative
β-Cryptoxanthin ((3R)-β-Cryptoxanthin) is an orally active carotenoid found in fruits and vegetables such as angerines, red peppers, and pumpkin. β-Cryptoxanthin inhibits prevents osteoclast formation and inhibits bone resorption. β-Cryptoxanthin maintains retinol status in vivo. β-cryptoxanthin shows anti-inflammation and anticancer activity. β-Cryptoxanthin can be used for the researches of osteoporosis and bladder carcer .

HY-N2983

Cajanin	Flavonoids Classification of Application Fields Leguminosae Other Diseases Phenols Polyphenols Red seaweeds Plants Disease Research Fields Isoflavones Source Classification	Tyrosinase
Cajanin is a potent and orally active anti-melanogenic agent. Cajanin shows antiproliferative activity in MNT1 Cells. Cajanin efficiently decreases the melanin content. Cajanin down-regulates the mRNA and protein expression levels of MITF, tyrosinase, TRP-1 and Dct (TRP-2). Cajanin induces cell cycle arrest at G2/M and S phase. Cajanin stimulates osteoblast proliferation. Cajanin has the potential for the research of human hyperpigmented disorders and menopausal osteoporosis .

HY-N0381

Maackiain 1 Publications Verification DL-Maackiain	Infection Structural Classification Natural Products Monophenols other families Classification of Application Fields Phenols Plants Disease Research Fields Source Classification	Keap1-Nrf2 p38 MAPK NOD-like Receptor (NLR) NF-κB mTOR Monoamine Oxidase Nuclear Factor of activated T Cells (NFAT) PKC Apoptosis Pyroptosis Autophagy Dengue Virus
Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever 。

HY-N2157

Pteryxin 1 Publications Verification (+)-Pteryxin	Coumarins Phenylpropanoids Umbelliferae Plants Achillea atrata L. Source Classification	Cholinesterase (ChE) NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS) Nuclear Factor of activated T Cells (NFAT) p38 MAPK
Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC₅₀=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca ²⁺-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease .

HY-126109

(±)-8-Prenylnaringenin	Structural Classification Flavonoids Humulus lupulus L. Flavonones Plants Moraceae Source Classification	Estrogen Receptor/ERR Apoptosis
(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ERα and ERβ with IC₅₀s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .

HY-N1403

Tigogenin	Classification of Application Fields Metabolic Disease Agavaceae Plants Agave sisalana Perr. ex Engelm. Disease Research Fields Steroids Source Classification	Apoptosis
Tigogenin is a steroidal sapogenins. Tigogenin can inhibit adipocytic differentiation and induce osteoblastic differentiation in mouse bone marrow stromal cells. Tigogenin can inhibit cells proliferation and induce apoptosis. Tigogenin can be used for the researches of cancer, inflammation, immunology, metabolic and cardiovascular disease, such as mammary gland carcinoma, rheumatoid arthritis, osteoporosis and atherosclerosis .

HY-N4119

Neoeriocitrin	Structural Classification Flavonoids other families Flavonones Phenols Polyphenols Plants Source Classification	Phosphatase Cholinesterase (ChE) p38 MAPK Apoptosis Autophagy
Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease .

HY-N2135

Puerarin 6''-O-Xyloside	Structural Classification Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Isoflavones Source Classification	Apoptosis Caspase Bcl-2 Family Tyrosinase
Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC₅₀ of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar .

HY-107245

Segetalin B 2 Publications Verification	Vaccaria segetalis (Neck.) Garcke Classification of Application Fields Cyclopeptides Metabolic Disease Plants Disease Research Fields Caryophyllaceae Source Classification	Estrogen Receptor/ERR Sirtuin RUNX
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .

HY-N3312

Matairesinol	Infection Structural Classification other families Classification of Application Fields Anti-aging Lignans Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Source Classification	p38 MAPK JNK NF-κB
Matairesinol is an orally active bioactive compound with anti-inflammatory, antioxidant and anticancer activities. Matairesinol inhibits the phosphorylation of MAPK, JNK and NF-κB, downregulates RANKL-induced NFATc1 expression and activity, and suppresses the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol can be used in research related to sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis and cancer .

HY-116474

Viridicatol	Infection Alkaloids Structural Classification Monophenols Microorganisms Classification of Application Fields Phenols Quinoline Alkaloids Disease Research Fields Source Classification	ERK JNK MMP p38 MAPK STAT Fungal Bacterial NO Synthase PGE synthase NF-κB Wnt β-catenin
Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .

HY-N0805A

Alisol B 1 Publications Verification	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Metabolic Disease Alismataceae Plants Disease Research Fields Source Classification	Epoxide Hydrolase CaMK Autophagy Apoptosis
Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a K_i of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G₁ phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer .

HY-N2156

Paeonolide	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Plants Paeoniaceae Inflammation/Immunology Disease Research Fields Paeonia suffruticosa Andr. Source Classification	ERK TGF-beta/Smad Wnt β-catenin JNK p38 MAPK
Paeonolide, found in Paeonia suffruticosa, is an ERK1/2 activator. Paeonolide promotes early and late osteoblast differentiation, stimulates pre-osteoblast transmigration, and activates the BMP-Smad1/5/8, Wnt-β-catenin, JNK and p38 pathways. Paeonolide can be used for the research of osteoporosis, periodontitis .

HY-B1361

Estropipate Piperazine estrone sulfate; Estrone sulfate piperazine salt	Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Estrogen Receptor/ERR
Estropipate is a form of estrogen, used to treat symptoms of menopause, also used to prevent osteoporosis.

HY-N0015R

Astragalin (Standard) Astragaline (Standard); 3-Glucosylkaempferol (Standard); Kaempferol 3-β-D-glucopyranoside (Standard)	Flavonols Structural Classification Flavonoids Microorganisms Phenols Polyphenols Plants Thesium chinense Turcz. Source Classification Santalaceae	Reference Standards Apoptosis NF-κB
Astragalin (Standard) is the analytical standard of Astragalin. This product is intended for research and analytical applications. Astragalin (Astragaline) a flavonoid with anti-inflammatory, antioxidant, anticancer, bacteriostatic activity. Astragalin inhibits cancer cells proliferation and migration, induces apoptosis. Astragalin is orally active and provides nerve and heart protection, and resistance against and osteoporosis .

HY-109569

Vitamin K2	Other Terpenoids Structural Classification Classification of Application Fields Terpenoids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Autophagy Apoptosis Interleukin Related
Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma .

HY-W012980R

Isovaleric acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite AMPK PKA
Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .

Cat. No.	Product Name	Chemical Structure

HY-N0390S1

L-Glutamine-13C5

Maximum Cited Publications

9 Publications Verification

L-Glutamine- ¹³C₅ is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S

L-Glutamine-15N

3 Publications Verification

L-Glutamine- ¹⁵N is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S8

L-Glutamine-15N2

1 Publications Verification

L-Glutamine- ¹⁵N₂ is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S9

L-Glutamine-15N-1

3 Publications Verification

L-Glutamine- ¹⁵N-1 is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S2

L-Glutamine-d5

1 Publications Verification

L-Glutamine-d₅ is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S6

L-Glutamine-13C5,15N2

L-Glutamine- ¹³C₅, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-A0020S

Eldecalcitol-d6
Eldecalcitol-d₆ is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.

HY-165607S

MCB-22-174

MCB-22-174 is a deuterated Piezo1 agonist, with an EC₅₀ value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca ²⁺ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP) .

HY-N0390S5

L-Glutamine-1-13C

1 Publications Verification

L-Glutamine-1- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S4

L-Glutamine-5-13C

L-Glutamine-5- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-B2156S

Menaquinone-4-d7
Menaquinone-4-d₇ (Vitamin K2(MK-4)-d7) is the deuterium labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.

HY-N0390S3

L-Glutamine-13C5,15N2,d5

L-Glutamine- ¹³C₅, ¹⁵N₂,d₅ is the deuterium, ¹³C-, and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-B0631S

Alendronic acid-d6
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .

HY-169332

Piezo1 agonist 1-d2

Piezo1 agonist 1-d2 is a Piezo1 agonist and osteogenesis promoter with an EC₅₀ of 2.21 μM. Piezo1 agonist 1-d2 activates Piezo1 and induces calcium ion influx in mesenchymal stem cells. Piezo1 agonist 1-d2 activates the Erk signaling pathway and promotes osteogenesis of mesenchymal stem cells. Piezo1 agonist 1-d2 alleviates disuse osteoporosis in a hindlimb unloading rat model. Piezo1 agonist 1-d2 can be used for research on osteoporosis .

HY-10003S

Alfacalcidol-d7
Alfacalcidol-d₇ is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis .

HY-B0515AS

Ibandronic Acid-d3 sodium salt
Ibandronic Acid-d₃ (sodium) is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis[1][2].

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0515AS1

Ibandronic acid-d3
Ibandronic acid-d₃ is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.

HY-123047S

Tibolone-d5
Tibolone-d₅ is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .

HY-B2156S1

Menaquinone-4-13C6
Menaquinone-4- ¹³C₆ is the ¹³C-labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.

HY-W698952S

3β hydroxy Tibolone-d5
3β hydroxy Tibolone-d₅ is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .

HY-108685S

Alendronate-d4 sodium
Alendronate-d₄ (sodium) (Alendronic acid-d₄ (monosodium salt)) is deuterium labeled Alendronate sodium. Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .

HY-13738S2

Raloxifene-d4 hydrochloride
Raloxifene-d₄ (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-13738S

Raloxifene-d4
Raloxifene-d₄ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-13738S3

Raloxifene-d10
Raloxifene-d₁₀ is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .

HY-B0723S

Ospemifene-d4
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC₅₀ values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects .

HY-B0005AS

Toremifene-d6
Toremifene-d₆ is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 μM and 2.6 μM, respectively .

HY-13777S

Zoledronic acid-d5
Zoledronic acid-d₅ is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .

HY-B0005S1

Toremifene-d6 hydrochloride
Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 µM and 2.6 µM, respectively .

HY-B0005S

Toremifene-d6 citrate
Toremifene-d₆ (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 μM and 2.6 μM, respectively .

HY-W743417

(-)-Norgestrel-d6
(-)-Norgestrel-d₆ is the deuterium labeled Levonorgestrel (HY-B0257). Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma .

HY-A0031S

Bazedoxifene-d4

Bazedoxifene-d₄ is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].

HY-A0031S2

Bazedoxifene-d4 acetate

Bazedoxifene-d₄ (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].

HY-117985S

Evogliptin-d9

Evogliptin-d₉ (DA-1229-d₉) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .

HY-N2393S

Kukoamine B-d5 dihydrochloride
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .

HY-16322S

Minodronic acid-d4

Minodronic acid-d₄ (YM-529-d₄) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

HY-N2037AS1

Higenamine-d4-1 hydrochloride

Higenamine-d₄-1 (Norcoclaurine-d₄-1) hydrochloride is deuterium labeled Higenamine (hydrochloride). Higenamine hydrochloride is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-N0390S7

L-Glutamine-15N2,d5

L-Glutamine- ¹⁵N₂,d₅ is the deuterium and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-P0059S

Teriparatide-d10
Teriparatide-d₁₀ (Human parathyroid hormone-(1-34)-d₁₀) is the deuterium labeled Teriparatide (HY-P0059). Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research .

Cat. No.	Product Name		Classification

HY-B0257

Levonorgestrel 2 Publications Verification D-Norgestrel		Alkynes
Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma .

HY-121528

Nilestriol Nylestriol; EE3CPE		Alkynes
Nilestriol is a estriol derivative, which inhibits osteoporosis on ovariectomized rats or postmenopausal women .

HY-148908

TNF-α-IN-8		Azide
TNF-α-IN-8 (compound I-42) is a TNF-α inhibitor. TNF-α-IN-8 is an isoindole-imide compound. TNF-α-IN-8 can be used for the research of cancer, heart disease, osteoporosis, inflammatory, allergic and autoimmune diseases . TNF-α-IN-8 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15893G

DMOG Dimethyloxallyl Glycine	Autophagy HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
DMOG (GMP) is the GMP level of DMOG (HY-15893). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

HY-15001G

Stemregenin 1 SR1	Aryl Hydrocarbon Receptor	Cancer
Stemregenin 1 (SR1) (GMP) is a GMP-grade Stemregenin 1 (HY-15001). GMP-grade small molecules can be used as adjuvants in cell therapy. Stemregenin 1 is a potent aryl hydrocarbon receptor (AhR) antagonist with an IC₅₀ of 127 nM. Stemregenin 1 (GMP) can competitively bind to AhR and inhibit its nuclear translocation, inhibiting osteoclastogenesis and promoting hematopoietic progenitor cell expansion by blocking the AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway. Stemregenin 1 (GMP) can be used for the study of osteoporosis, in vitro expansion of hematopoietic stem cells, and the study of the mechanism of bone metabolic diseases .

HY-N0390G

L-Glutamine	mTOR NF-κB STAT HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

osteoporosis

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products